HOME >> MEDICINE >> NEWS
Hopkins' Peter Agre receives 2003 Nobel Prize in chemistry

Peter Agre, M.D., 54, professor of biological chemistry at the Johns Hopkins University School of Medicine, today was awarded the 2003 Nobel Prize in Chemistry by the Royal Swedish Academy of Sciences. The Academy recognized him for his laboratory's 1991 discovery of the long-sought "channels" that regulate and facilitate water molecule transport through cell membranes, a process essential to all living organisms.

Agre (pronounced AHG-ray) shares this year's prize with Roderick MacKinnon, a Rockefeller University scientist who determined the spatial structure of cell membrane channels that control passage of salts.

The discovery of the water channel, dubbed "water pore" or aquaporin, ushered in a golden age of biochemical, physiological and genetic studies of these proteins in bacteria, plants and mammals, and fundamental understanding -- at the molecular level -- of malfunctioning channels associated with many diseases of the kidneys, skeletal muscle and other organs. Working from this basic knowledge, scientists are searching for drugs that can specifically target water channel defects.

"It is a remarkable honor to receive a Nobel Prize, because it not only recognizes discoveries, but also their usefulness to the advancement of fundamental science," says Agre, a member of Hopkins' Institute for Basic Biomedical Sciences. "It is amazing and gratifying that the Nobel committee feels our work has accomplished that milestone in just 12 years. That's warp speed in molecular chemistry and it could never have happened as fast as it did without the wonderful resources and collaborators available at Johns Hopkins. This is an honor for the entire Hopkins family."

"This is a great day for the school of medicine and the university at large," says Edward D. Miller, M.D., dean of the medical faculty and CEO of Johns Hopkins Medicine. "There are few happier occasions to celebrate at an academic medical center."

"This is a terrific day fo
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
8-Oct-2003


Page: 1 2 3 4

Related medicine news :

1. Hopkins young researchers honored for their contributions
2. Peter H. Arger, MD, receives the 2004 AIUM William J. Fry Memorial Lecture Award
3. UIC professor receives international humanitarian award
4. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
5. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
6. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
7. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
8. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
9. American Academy of Neurology program receives Grassroots Award
10. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
11. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hopkins Peter Agre receives Nobel Prize chemistry

(Date:5/20/2013)... CosmosID, a leading data mining solutions company for health ... results on analysis of labeling claims for the composition ... The Food and Drug Administration (FDA) and CosmosID conducted ... four of which have been reported at the American ... was to compare the identity of species and strains ...
(Date:5/20/2013)... Sporturf, an international manufacturer and builder of synthetic ... Midwest with the opening of the company’s third regional ... is under the leadership of President Craig Shonk, and ... , “This strategic move opens up a market ... Shonk. “Bringing an ISO manufacturer and a Midwest-based ASBA ...
(Date:5/20/2013)... Online education provides the convenience, flexibility and cost-saving ... According to the American Heart Association, 27% of ... to eLearning due to changing economic conditions. The ... budgets, but it is also proven to enhance ... higher retention of content is probable, given the ...
(Date:5/20/2013)... as a consequence of diabetic foot ulcer that does ... this situation are very limited. In his doctoral thesis ... Department of Medical Biochemistry and Biophysics at Ume University ... may completely change the lives of millions of patients. ... chronic wounds that largely impair the quality of life ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 BenefitMall, ... of employee benefit, payroll products and services and ... both are selected as finalists for the 2013 American ... Company of the Year category, and CompuPay is a ... finalist will ultimately be a Gold, Silver or Bronze ...
Breaking Medicine News(10 mins):Health News:CosmosID unveils new tool for faster, specific and accurate testing of probiotics products 2Health News:Sporturf Expands into the Midwestern U.S. 2Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Discovery of a novel medicine for the treatment of chronic wounds 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3
(Date:5/20/2013)... ALISO VIEJO , Kalifornien, 20. Mai ... heute bekannt, dass das Unternehmen die CE-Kennzeichnung ... Implantate zur Embolisation von Aneurysmen erhalten hat. ... in Europa bereits mit der kontrollierten Einführung ... Profil bietet die SL-Produktfamilie auch ein verbessertes ...
(Date:5/20/2013)... Enrollment of patients with Type 2 diabetes ... trial of product candidate NewMet ™, a delayed-release ... 2 diabetes. Elcelyx expects to complete enrollment of 240 ... of the trial,s primary endpoint of change in fasting ... read-out for long-term glucose lowering and weight benefits is ...
(Date:5/20/2013)... 20, 2013  AbbVie (NYSE: ABBV ... 3 clinical study called SONAR (Study Of Diabetic ... the investigational compound atrasentan - when added to standard ... patients with stage 2 to 4 chronic kidney ... a large, multinational, double-blind, placebo-controlled clinical study that ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
Cached News: